Lexaria Bioscience (CSE: LXX) (OTCQB: LXRP) reported this morning that it has been granted a patent from the United States Patent and Trademark Office (“USPTO”) increasing its intellectual property (“IP”) hold of its DehydraTECH™ technology. The newly-issued patent covers the use of DehydraTECH™ technology as a delivery platform for a broad range of Active Pharmaceutical Ingredients (“APIs”) including all cannabinoids, fat soluble vitamins, non-steroidal anti-inflammatory pain medications (“NSAIDs”), and nicotine. In addition, Lexaria continues to advance all of its other patent applications worldwide. “This ground-breaking, patented IP builds a foundation for new business opportunities in 2018 including what could be the world’s first nicotine edibles for the smokeless tobacco industry or improved new products for NSAID-derived pain management, as well as in the rapidly growing cannabis market,” Lexaria Bioscience chief executive officer Chris Bunka stated in the news release.
To view the full press release, visit http://cnw.fm/2IonK
About Lexaria Bioscience Corp.
Lexaria Bioscience Corp. has developed and out-licenses its disruptive delivery technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and was granted its first patents in the USA and in Australia related to edible forms of cannabinoids. Lexaria’s technology provides increases in intestinal absorption rates; more rapid delivery to the bloodstream; and important taste-masking benefits, for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules. For more information, visit the company’s website at www.LexariaEnergy.com.
More from CannabisNewsBreaks
CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
For more information please visit https://www.CannabisNewsWire.com